# PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

> **NCT05172596** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 146 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** PHE885

## Key facts

- **NCT ID:** NCT05172596
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-03
- **Primary completion:** 2025-05-21
- **Final completion:** 2025-05-21
- **Target enrollment:** 146 (ACTUAL)
- **Why stopped:** The study was terminated since the sponsor made the decision to discontinue further development of the study drug durcabtagene autoleucel (PHE885).
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05172596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05172596, "PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05172596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*